Offer - Urjas Oil for just ₹ 1 X
Erbitux is a prescription drug, available for use as Infusion, Injection. Colorectal Cancer are some of its major therapeutic uses. Other than this, Erbitux has some other therapeutic uses, which have been discussed ahead.
The right dosage of Erbitux depends on the age, gender, and medical history of the patient. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
Erbitux also has some side effects, the most common being Nausea or vomiting, Headache, Skin Rash. Some other side effects of Erbitux have been listed ahead. Normally, these side effects of Erbitux are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
Erbitux's effect during pregnancy is Severe and Severe while nursing. Further, the section on Erbitux related warnings talks about Erbitux's effects on the liver, heart and kidney.
Erbitux is not recommended if you suffer from certain medical conditions as it can have adverse effects. Heart Disease, Calcium Deficiency, Potassium Deficiency are examples of such conditions. Other conditions have been mentioned below in the Erbitux contraindications section.
Drug reaction of Erbitux with other medicines has been reported. A complete list of these interactions is given below.
In addition to the above precautions for Erbitux, it is important to know that it is not safe while driving, and is not habit-forming.
Erbitux is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Erbitux safe for pregnant women?
Erbitux should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Erbitux safe during breastfeeding?
Erbitux may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Erbitux on the Kidneys?
Erbitux does not damage the kidneys.
What is the effect of Erbitux on the Liver?
Erbitux is not harmful for the liver.
What is the effect of Erbitux on the Heart?
The heart can be affected by Erbitux. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart the medicine only after medical advice.
Erbitux should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Erbitux unless your doctor advises you to do so -
Is this Erbitux habit forming or addictive?
No, there is no any evidence that Erbitux is addictive.
Is it safe to drive or operate heavy machinery when consuming?
After taking Erbitux, you should not drive or work on any heavy machine, as Erbitux can make you drowsy.
Is it safe?
Yes, Erbitux is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
No, Erbitux is not used to treat mental disorders.
Interaction between Food and Erbitux
Taking Erbitux with food does not harm your health.
Interaction between Alcohol and Erbitux
Information about the interaction of Erbitux and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Erbitux® (cetuximab)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 870
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 317-319